Neurofibromatoses - Pipeline Review, H1 2016

  • ID: 3775414
  • Drug Pipelines
  • 73 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • AstraZeneca Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE
Neurofibromatoses - Pipeline Review, H1 2016

Summary

‘Neurofibromatoses - Pipeline Review, H1 2016’, provides an overview of the Neurofibromatoses pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neurofibromatoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neurofibromatoses
- The report reviews pipeline therapeutics for Neurofibromatoses by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neurofibromatoses therapeutics and enlists all their major and minor projects
- The report assesses Neurofibromatoses therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neurofibromatoses

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neurofibromatoses pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • AstraZeneca Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Neurofibromatoses Overview

Therapeutics Development

Pipeline Products for Neurofibromatoses - Overview

Pipeline Products for Neurofibromatoses - Comparative Analysis

Neurofibromatoses - Therapeutics under Development by Companies

Neurofibromatoses - Therapeutics under Investigation by Universities/Institutes

Neurofibromatoses - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Neurofibromatoses - Products under Development by Companies

Neurofibromatoses - Products under Investigation by Universities/Institutes

Neurofibromatoses - Companies Involved in Therapeutics Development

Alexion Pharmaceuticals, Inc.

Arno Therapeutics, Inc.

AstraZeneca Plc

CalAsia Pharmaceuticals, Inc.

Kolltan Pharmaceuticals, Inc.

Lixte Biotechnology Holdings, Inc.

Novartis AG

Pfizer Inc.

Neurofibromatoses - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AR-42 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

asfotase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FRAX-597 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KTN-0158 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OS-342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurofibromatoses Type I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hsp90-Alpha and TRAP 1 for Neurofibromatosis Type 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neurofibromatoses - Dormant Projects

Neurofibromatoses - Discontinued Products

Neurofibromatoses - Product Development Milestones

Featured News & Press Releases

May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Neurofibromatoses, H1 2016

Number of Products under Development for Neurofibromatoses - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Neurofibromatoses - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016

Neurofibromatoses - Pipeline by Arno Therapeutics, Inc., H1 2016

Neurofibromatoses - Pipeline by AstraZeneca Plc, H1 2016

Neurofibromatoses - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016

Neurofibromatoses - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016

Neurofibromatoses - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016

Neurofibromatoses - Pipeline by Novartis AG, H1 2016

Neurofibromatoses - Pipeline by Pfizer Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Neurofibromatoses - Dormant Projects, H1 2016

Neurofibromatoses - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Neurofibromatoses, H1 2016

Number of Products under Development for Neurofibromatoses - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • AstraZeneca Plc
  • Novartis AG
  • Pfizer Inc.
  • MORE
Neurofibromatoses pipeline therapeutics constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Neurofibromatoses – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Neurofibromatoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neurofibromatoses Neurofibromatosis (commonly abbreviated NF; neurofibromatosis type 1 is also known as von Recklinghausen disease) is a genetically-inherited disorder in which the nerve tissue grows tumors (neurofibromas) that may be benign or may cause serious damage by compressing nerves and other tissues. The disorder affects all neural crest cells (Schwann cells, melanocytes and endoneurial fibroblasts). Cellular elements from these cell types proliferate excessively throughout the body, forming tumors; melanocytes also function abnormally in this disease, resulting in disordered skin pigmentation and café au lait spots. The tumors may cause bumps under the skin, colored spots, skeletal problems, pressure on spinal nerve roots, and other neurological problems. The molecules developed by Companies in Phase II, Phase 0, Preclinical and Discovery stages are 3, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Alexion Pharmaceuticals, Inc.
Arno Therapeutics, Inc.
AstraZeneca Plc
CalAsia Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc.
Lixte Biotechnology Holdings, Inc.
Novartis AG
Pfizer Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll